MedPro Rx makes Facebook debut
RALEIGH, N.C. — A specialty infusion pharmacy has joined the social media realm.
MedPro Rx’s president, Nancy McFarlane, said that the company has launched a Facebook page, which will share MedPro Rx’s news, updates, blog posts and photos with its community. Additionally, the page will expand the company’s online presence and customer service focus for clients, healthcare consumers, providers and third-party payers, McFarlane said.
“Our Facebook page is a great tool that will enable us to better communicate our mission, connect information and work with our community," she said. “At MedPro Rx, we are always searching for the latest ways to provide the best possible customer service experiences for our clients, and the addition of Facebook is one more venue we can utilize.”
Amanda Brown named BioPlus’ Rx coordinators director
ALTAMONTE SPRINGS, Fla. — BioPlus Specialty Pharmacy has promoted its supervisor of Rx coordinators.
Amanda Brown, who joined the company in 2003, now will serve as director of Rx coordinators. In this role, she will manage and train BioPlus’ sales team, but also will be involved in building business relationships with prescribers, achieving territorial goals and maximizing potential revenue for BioPlus.
“Amanda has been a key part of our sales team success, and we are thrilled to promote her to this important position. This promotion is a great example of matching leadership talent to our business priority here at BioPlus, which remains providing medications to patients while eliminating workloads from physician offices,” said Stephen Vogt, president and CEO of BioPlus.
Valeant seeks to buy Cephalon
MISSISSAUGA, Ontario — Canadian drug maker Valeant Pharmaceuticals has proposed to buy Cephalon for $5.7 billion, Valeant said Tuesday.
The buyout offer, equal to $73 per share, includes a 29% premium over Cephalon’s stock price. Valeant noted it had made previous offers, but was “disappointed by Cephalon’s unwillingness to engage in discussions in a timely manner.”
“We have taken a close look at Cephalon’s business and believe we put forward a very compelling offer for Cephalon’s stockholders,” Valeant chairman and CEO J. Michael Pearson said. “We are also committed to trying to find additional value if we are allowed to conduct due diligence.”
Cephalon makes the sleep disorder drugs Nuvigil (armodafinil) and Provigil (modafinil) and the pain treatment Fentora (fentanyl), among others. Valeant makes such drugs as the topical acne treatment Acanya Gel (clindamycin phosphate and benzoyl peroxide) and various branded generics.